Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 29;12(12):3569. doi: 10.3390/cancers12123569

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

A large petroclival meningioma treated by mSRS. (A) The dose–volume histograms quantify the treatment characteristics. The prescription dose was 25 Gy in five fractions. The PTV was 16.8 cc. The nCI was 1.3 and the tumor coverage 95.4%. Maximal doses to the optic chiasm and left optic nerve were 16.9 Gy and 14 Gy, respectively. (B) Doses distribution in the three spatial planes showing the rapid dose fall-off from 80% to 15%, despite the large volume of the lesion. (C) Pre-treatment MR (A) and 3-year control MR (B) showing satisfactory tumor shrinkage.

A large petroclival meningioma treated by mSRS. (A) The dose–volume histograms quantify the treatment characteristics. The prescription dose was 25 Gy in five fractions. The PTV was 16.8 cc. The nCI was 1.3 and the tumor coverage 95.4%. Maximal doses to the optic chiasm and left optic nerve were 16.9 Gy and 14 Gy, respectively. (B) Doses distribution in the three spatial planes showing the rapid dose fall-off from 80% to 15%, despite the large volume of the lesion. (C) Pre-treatment MR (A) and 3-year control MR (B) showing satisfactory tumor shrinkage.